New Trial of Constipation Predominant IBS Treatment Now Recruiting at 69 Centers in U.S. & Canada

This Phase 2b trial involving a drug taken orally for symptom relief of constipation predominant IBS (ClinicalTrials.gov number NCT00547469) is enrolling female patients only – at 69 sites in more than 20 U.S. states and across Canada.

The drug – pumosetrag (DDP733) – is said to mimic the effect of the neurotransmitter serotonin, which is known to be involved in control of the gastrointestinal system.

For details of this large-scale pharmaceutical firm-sponsored study, visit the study listing at ClinicalTrials.gov.

For those who may be interested in participating, the ClinicalTrials.gov description includes a link to a separate site with more information about the trial and the trial sites (http://www.pictureibs.com) – plus an interactive eligibility-screening questionnaire.

1 Star2 Stars3 Stars4 Stars5 Stars (94 votes, average: 3.55 out of 5)
Loading...



Leave a Reply